Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00141596
Status:
TERMINATED
Last Update Posted:
2015-06-09
First Post:
2005-08-31
Brief Title:
Extracellular Fluid in Resistant Hypertension
Sponsor:
St Georges University of London
Organization:
St Georges University of London
Study Overview
Official Title:
A Study to Investigate the Contribution of Extracellular Fluid Volume Expansion to Drug Resistant Hypertension
Status:
TERMINATED
Status Verified Date:
2007-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Insufficient accrual rate
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The optimal treatment of drug resistant defined as BP 14085 despite three anti-hypertensive drugs including a diuretic is not well defined This study aims to test the hypothesis that resistant hypertension is caused by excessive expansion of extracellular fluid volume A secondary objective is to study which of three different antihypertensive drugs would be most useful in drug resistant hypertension
Detailed Description:
Following recruitment subjects will have ECV measured by 51Cr-EDTA determination of GFR with Brochner-Mortensen correction applied Subjects then receive the following drugs in a randomised fashion for a period of four weeks each with BP ECV measurement at end of each period doxazosin GITS Cardura XL 4 mg bd frusemide 40 mg bd amiloride 5 mg bd placebo
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None